PTO/SB/81 (11-04)

Approved for use through 11/30/2005. OMB 0651-0035

POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM

Under the <u>Paperwork Reduction</u> Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number		
POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM	Application Number	10/785,449
	Filing Date	FEBRUARY 24, 2004
	First Named Inventor	TRACEE EIDENSCHINK
	Title	ROTATABLE CATHETER ASSEMBLY
	Art Unit	3734
	Examiner Name	VI X. NGUYEN
	Attorney Docket Number	1001 2265101

I hereby revoke all previous powers of attorney given in the above-identified application.			
I hereby appoint:			
Practitioners associated with the Customer Number:	28075		
OR L			
Practitioner(s) named below:			
Name	Registration Number		
l -			
as my/our attorney(s) or agent(s) to prosecute the application identified at	pove, and to transact all business in the United States Patent and		
Trademark Office connected therewith.			
Please recognize or change the correspondence address for the above-in	lentified application to:		
The address associated with the above-mentioned Customer No.	umber:		
OR			
The address associated with Customer Number			
OR			
Firm or individual Name			
Address			
City	State Zip		
Country			
Telephone	Fax		
lam the			
Applicant/Inventor.			
Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96			
Signature of Applicant			
16 8 11 11			
Signature Stout Make N	Date AUGUST 29, 2008		
Name Steven A. McAuley V Title and Company Branch Search A. McAuley V Little and Company Branch Search A. McAuley V Little and Company Branch Search Sear	Telephone 763, 999, 2425		
	1 Course E		
NOTE. Signatures of all the inventors or assignees of record-of the entire interest or signature is required, see below.	their representative(s) are required. Submit multiple forms if more than one		
*Total of forms are submitted.			

This confliction of coloration is required by 3 CFH 6131, 162, and 13.3. The elements is required to other or retain a beart by the subtle-when it is fits jobs. The coloration is required by 3 U.S. of 12 and 3 CFB 11 and 11.4. This is collection is extended by 35 U.S. of 12 and 3 CFB 11 and 11.4. This is collection is extended by 35 U.S. of 12 and 3 CFB 11 and 11.4. This is collection is extended by 15 U.S. of 12 and 3 CFB 11 and 11.4. This is collection is extended by 15 U.S. of 12 and 3 CFB 11 and 11.4. This is collection in the coloration of the coloration is considered application form to the USPTO. Time will vary deponding upon the individual case. And coloration of the coloration o

LIMITED AUTHORIZATION TO ACT ON BEHALF OF ASSIGNEE REGARDING CERTAIN PATENT MATTERS EFFECTIVE THROUGH: December 31, 2008

EFFECTIVE THROUGH: December 31, 2008

I, Lawrence J. Knopf, as Senior Vice President and Deputy General Counsel of Boston Scientific Corporation, the controlling corporation of:

A-Med Systems, Inc.; Advanced Stent Technologies, Inc.; AFx, Inc.; AMS Medinvent S.A.; BEI Medical Systems; BEI Medical Systems Operating Company (formerly known as Xylog Corporation); BEI Medical Systems International, Inc.; Boston Scientific BV: Boston Scientific Corporation Northwest Technology Center, Inc.: Boston Scientific Cupertino Corp.: Boston Scientific Ireland Limited, Boston Scientific Japan KK; Boston Scientific Limited, Boston Scientific Neuromodulation Corporation; Boston Scientific Scimed, Inc. (formerly known as Schneider (USA), Inc.); Boston Scientific Scimed, Inc. (formerly known as Scimed Life Systems, Inc.); Cardiac Pacemakers, Inc.; Cardiac Pathways Corporation, Cardiothoracic Systems, Inc.: Cardiovascular Innovations Canada, Inc.; Catheter Innovations Corp.; Corvita Canada, Inc.; Corvita Corporation; Corvita Europe S.A., CryoVascular Systems, Inc., Embolic Protection, Inc., Embro Vascular, LLC; Enable Medical Corporation: EndoTex Interventional Systems, Inc.: Endovascular Technologies, Inc. (EVT); Enteric Medical Technologies, Inc., EP Technologies, Inc., Fidus Medical Technology Corporation; Guidant Corporation; Guidant Holdings, Inc.; Guidant Intercontinental Corporation; Guidant Investment Corporation; Guidant Puerto Rico Sales Corporation; Guidant Sales Corporation; Heart Technologies; Inflow Dynamics Inc.; Intermedics, Inc.; Interventional Technologies, Inc.; Laboratoires Corvita S.A.R.L.; Meadox Medicals, Inc.; NAMIC Eireann Limited; NAMIC International, Inc.; Nilo Holding, S.A.; Origin Medsystems, Inc.; Precision Vascular Systems, Inc.; Prohold Medical Corporation; Prohold Technologies, Inc.; Provasis Therapeutics, Inc.; Quanum Corporation; Radio Therapeutics Corporation; Rubicon Medical Corporation; Rubicon Medical, Inc.; Schneider (Europe) GmbH; Schneider Belgium NV; Schneider Holland BV; Schneider Ireland BV; Schneider Puerto Rico (formerly known as NAMIC Caribe, Inc.); Schneider/NAMIC; Scimed Life Systems, Inc.; Smart Therapeutics, Inc.; Sub-Q, Inc.; Symbiosis Corporation; Target Therapeutics, Inc.; TriVascular, Inc.; and Vesica;

hereby authorize the following registered patent attorneys/agents (1) to act on behalf of any of the corporations identified above, including Boston Scientific Corporation, with regard to any matters before the United States Patent and Trademark Office, any foreign patent offices, and any international patent entities, (2) to execute power of attorney documents on behalf of any of the corporations identified above, including Boston Scientific Corporation, to appoint and/or lestablish any attorneys, agents, and/or law firms to act on behalf of any of the corporations identified above, including Boston Scientific Corporation, any foreign or international patent applications filed with any foreign and/or international patent offices, and (3) to execute assignment and ownership documents on behalf of any of the corporations identified above, including Boston Scientific Corporation, with regard to any matters before the United States Patent and Trademark Office, any foreign patent offices, and any international patent offices:

Philip H. Lee

Alana Bergman Reg. No. 47,420	Kurt W. LockwoodReg. No. 40,704
James R. Chiapetta Reg. No. 39,634	Jeffrey Z. MannReg. No. 51,994
Richard R. Clapp Reg. No. 31,751	Steven A. McAuleyReg. No. 46,084
Jeffrey P. CookReg. No. 48,649	Todd P. MessalReg. No. 42,883
Luke R. Dohmen Reg. No. 36,783	Tyler L. NasiedlakReg. No. 40,099
Peter J. Gafner Reg. No. 36,517	William J. ShawReg. No. 43,111
Lori J. Heinrichs Reg. No. 43,667	Sarah G. StolpmanReg. No. 57,000
Albert K. Kau	

Lawrence J. Knopf, Senior Vice President and Deputy General Counsel

Victoria Aguilera Poissant....... Reg. No. 56.871

1 / 4 /08 Date

Reg. No. 50.645

COMMONWEALTH OF MASSACHUSETTS

SS.

COUNTY OF MIDDLESEX

On this 9th, day of January 3008 before me personally appeared Lawrence J. Knopf to me known and known to me to be the person described in and who executed the foregoing instrument, and he duly acknowledged to me that he executed the same for the uses and purposes set forth herein.

Notary Public

Approved for use through 07/31/2008. OMB 0651-0051
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)		
Applicant/Patent Owner: TRACEE EIDENSCHINK		
Application No./Patent No.: 10/785,449 Filed/Issue Date: FEBRUARY 24, 2004		
Entitled: ROTATABLE CATHETER ASSEMBLY		
SCIMED LIFE SYSTEMS, INC. (Name of Assignee) a CORPORATION (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)		
states that it is: 1		
The extent (by percentage) of its ownership interest is%)		
in the patent application/patent identified above by virtue of either:		
A A An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel Frame from from the Trademark Office at Reel Frame from from from the Copy thereof is attached.		
OR B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:		
1. From: TRACEE EIDENSCHINK To: SCIMED LIFE SYSTEMS, INC. The document was recorded in the United States Patent and Trademark Office at Reel 015021 Frame 0473 or for which a copy thereof is attached.		
From: To: The document was recorded in the United States Patent and Trademark Office at		
Reel, Frame, or for which a copy thereof is attached.		
3. From: To:		
The document was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.		
Additional documents in the chain of title are listed on a supplemental sheet.		
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.		
[NOTE: A separate copy (<i>i.e.</i> , a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]		
The undersigned (whose title is sympliced below) is authorized to act on behalf of the assignee.		
Signature Date		
J. SCOT WICKHEM 612.677.9050 Printed or Typed Name Telephone Number		
ATTORNEY FOR APPLICANT(S)		
Title		

This coaction of information is required by 37 CFT. 2013.

Period of the coaction of information is required by 31 CFT. 2013.

Period of the coaction of information is required by 31 U.S. CFT. 2014 and 37 CFR. 11 and 11.4. This collidation is estimated the climitate to complete, including gashering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete in form and/or supplessions for reducing this butter, should be sent to the Child Loss. Any CFT. 2014 and 11.4. This collidation of the USPTO. The will vary depending upon the individual case. Any CFT. 2014 and 11.4. This collidation is completed application for the USPTO. The Will vary depending upon the individual case. Any CFT. 2014 and 11.4. This collidation is commended and the comment of the complete application for reducing this butter, should be sent to the Child be sent to the Child be sent to the Child CFT. 2014 and 11.4. This collidation is considered and the comment of t